Skip to main content

Nuwellis, Inc.

corporate_fare Company Profile

Nuwellis, Inc.

NUWE·NASDAQ·Life Sciences·CIK 0001506492

Nuwellis develops, manufactures, and sells medical devices for cardiorenal care, specifically focusing on ultrafiltration therapy to manage fluid in patients. The company's primary products are the Aquadex FlexFlow® and the Aquadex SmartFlow® systems, collectively known as the "Aquadex System." The Aquadex SmartFlow® system is approved for use in adult and pediatric patients weighing 20 kg or more who have fluid overload that has not responded to other medical treatments, including diuretics. This system can be used temporarily for up to eight hours or for extended periods longer than 8 hours for hospitalized patients. Fluid overload, also called hypervolemia, is a condition where there is an excessive amount of fluid in the blood, vital organs, and the space between cells, representing an expansion of the extracellular fluid volume. While some fluid is necessary for health, too much can lead to imbalances and health damage. Signs and symptoms of fluid overload can vary among patients but may include pulmonary edema/pleural effusion, peripheral edema, anasarca (skin swelling), ascites, jugular vein distention, and dyspnea.

Nuwellis, Inc. (NASDAQ:NUWE) is a publicly traded company in the Life Sciences sector. Wiseek monitors NUWE SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Former Directors Rebut Nuwellis's Characterization of Resignations, Citing Factual Discrepancies
  • Nuwellis Pediatric Category Hits 50% of U.S. Revenue in 2025, Marking Key Growth Milestone
  • Two Nuwellis Directors Resign Citing Disagreements and Alleged Failure to Provide Information
  • Two Directors Resign from Nuwellis Board Citing Governance Failures, Lack of Transparency, and Dilutive Transactions
  • Nuwellis Closes Acquisition of Rendiatech, Expanding Kidney Monitoring Technology Portfolio

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$8.27M
Net Income
-$17.52M
Diluted EPS
-$25.39
Op. Cash Flow
-$10.81M
Free Cash Flow
-$10.9M
Gross Profit
$5.12M
Operating Income
-$11.11M
Cash & Equivalents
$1.08M
Debt / Equity
0.00×
Net Margin
-211.9%
Shares Outstanding
1.69M sh
Source: 10-K · filed 2026-03-11 · accession 0001140361-26-009080
$0.1414 -0.00% today
52-week range · as of 2026-06-10 $0.132 – $25.95
Market cap
$1.82M
Volume
3.8M (1.4× avg)
3-mo avg 2.7M
Live data · 2026-06-14 06:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NUWE - Filings & News (Page 2)

NUWE
Apr 01, 2026, 4:45 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.1414 info
Change: -$0.9286 (-87%) info
Market Cap: $1.823M info
NUWE
Mar 31, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.16
Real-time Price: $0.1414 info
Change: -$1.02 (-88%) info
Market Cap: $1.823M info
NUWE
Mar 27, 2026, 5:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.1414 info
Change: -$0.8886 (-86%) info
Market Cap: $1.823M info
NUWE
Mar 27, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.1414 info
Change: -$0.9086 (-87%) info
Market Cap: $1.823M info
NUWE
Mar 17, 2026, 9:13 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.24
Real-time Price: $0.1414 info
Change: -$1.10 (-89%) info
Market Cap: $1.823M info
NUWE
Mar 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.26
Real-time Price: $0.1414 info
Change: -$1.12 (-89%) info
Market Cap: $1.823M info
NUWE
Mar 11, 2026, 6:25 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.37
Real-time Price: $0.1414 info
Change: -$1.23 (-90%) info
Market Cap: $1.823M info
NUWE
Mar 11, 2026, 5:24 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.34
Real-time Price: $0.1414 info
Change: -$1.20 (-89%) info
Market Cap: $1.823M info
NUWE
Mar 10, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $0.1414 info
Change: -$1.13 (-89%) info
Market Cap: $1.823M info
NUWE
Mar 10, 2026, 8:16 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.40
Real-time Price: $0.1414 info
Change: -$1.26 (-90%) info
Market Cap: $1.823M info
NUWE
Mar 10, 2026, 8:15 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.1414 info
Change: -$1.14 (-89%) info
Market Cap: $1.823M info
NUWE
Mar 06, 2026, 8:18 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.50
Real-time Price: $0.1414 info
Change: -$1.36 (-91%) info
Market Cap: $1.823M info
NUWE
Feb 26, 2026, 8:49 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.61
Real-time Price: $0.1414 info
Change: -$1.47 (-91%) info
Market Cap: $1.823M info
NUWE
Feb 09, 2026, 5:22 PM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $2.60
Real-time Price: $0.1414 info
Change: -$2.46 (-95%) info
Market Cap: $1.823M info
NUWE
Feb 03, 2026, 9:44 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $3.82
Real-time Price: $0.1414 info
Change: -$3.68 (-96%) info
Market Cap: $1.823M info
NUWE
Jan 30, 2026, 9:08 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.48
Real-time Price: $0.1414 info
Change: -$3.34 (-96%) info
Market Cap: $1.823M info
NUWE
Jan 23, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.22
Real-time Price: $0.1414 info
Change: -$2.08 (-94%) info
Market Cap: $1.823M info